CervoMed (CRVO) to Release Earnings on Friday

CervoMed (NASDAQ:CRVO) is anticipated to announce its earnings results before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $1.79 million for the quarter.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Stock Performance

Shares of CRVO opened at $8.50 on Friday. The firm has a market capitalization of $73.98 million, a price-to-earnings ratio of -4.19 and a beta of 1.84. The stock’s fifty day moving average is $3.85 and its 200-day moving average is $7.69. CervoMed has a one year low of $1.80 and a one year high of $25.92.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on CRVO. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a research note on Wednesday, December 11th. Roth Mkm raised their target price on CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, March 18th. Brookline Capital Management raised CervoMed from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Roth Capital raised shares of CervoMed to a “strong-buy” rating in a report on Thursday, December 5th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price objective on shares of CervoMed in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $27.50.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.